Free Trial
→ NEVER thought this would happen again (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.01
$0.00
▼
$0.10
$16K-0.4428,791 shs226 shs
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
-28.6%		$0.00
$0.00
▼
$0.10
$29K-9.660,087 shs4,590 shs
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$0.01
$0.00
$0.00
▼
$0.50
$20K3892.082,773 shsN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,720 shs1,947 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%0.00%+200.00%-99.21%-99.67%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-28.57%+150.00%-28.57%-80.00%-98.96%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
0.00%0.00%+11,100.00%+11.44%+11,100.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%0.00%+300.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.01
$0.00
▼
$0.10
$16K-0.4428,791 shs226 shs
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
-28.6%		$0.00
$0.00
▼
$0.10
$29K-9.660,087 shs4,590 shs
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$0.01
$0.00
$0.00
▼
$0.50
$20K3892.082,773 shsN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,720 shs1,947 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%0.00%+200.00%-99.21%-99.67%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-28.57%+150.00%-28.57%-80.00%-98.96%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
0.00%0.00%+11,100.00%+11.44%+11,100.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%0.00%+300.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00
N/AN/AN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
0.00
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.00N/AN/A($0.67) per share0.00
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$17.42M0.00N/AN/A$14.02 per share0.00
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.03N/AN/A$0.79 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%11/12/2026 (Estimated)
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%11/5/2026 (Estimated)
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
-$17.90M-$7.56N/AN/AN/AN/AN/AN/A11/13/2026 (Estimated)
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%N/A

Latest SYRS, CARM, CLVR, and BPTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026N/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
-$10.95N/AN/AN/A$4.05 millionN/A
11/5/2026N/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$0.1237N/AN/AN/A$4.66 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25

Institutional Ownership

CompanyInstitutional Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
6.92%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%

Insider Ownership

CompanyInsider Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
8.20%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1053.90 million5.73 millionNo Data
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
4641.85 million38.91 millionNo Data
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
2961.76 million1.61 millionNo Data
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
6826.83 million23.54 millionNo Data

Recent News About These Companies

Syros Pharmaceuticals stock remains tied to Nasdaq delisting process
October 30 at 10:47 PM  |  ad-hoc-news.deA
Syros approves wind-down: what it means for Syros Pharmaceuticals stock
October 6, 2026  |  ad-hoc-news.deA
Syros Pharmaceuticals stock trades at USD 0.0004 after delisting
October 4, 2026  |  ad-hoc-news.deA
SYRS stock reflects a 2025 Nasdaq delisting and wind down
September 30, 2026  |  ad-hoc-news.deA
Syros Pharmaceuticals stock holds steady as market data reset
September 23, 2026  |  ad-hoc-news.deA
Syros Announces Pricing of $75.6 Million Public Offering of Common Stock
July 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20210119006194/en/Syros-Announces-Pricing-of-%2475.6-Million-Public-Offering-of-Common-Stock
Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals
April 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/rege-nephro-buys-tamibarotene-related-assets-from-syros-pharmaceuticals/ar-AA1CX7u7
Syros Pharmaceuticals trading resumes
March 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/syros-pharmaceuticals-trading-resumes-1034427505
Syros Pharmaceuticals Plans to Wind Down Operations
March 1, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/syros-pharmaceuticals-plans-to-wind-down-operations-948b139e
Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock
March 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/syros-pharmaceuticals-voluntarily-delists-from-nasdaq-deregisters-common-stock-1034427422
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
February 28, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250228459350/en/syros-announces-voluntary-delisting-from-nasdaq-and-sec-deregistration/
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline
January 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/syros-pharmaceuticals-stock-hits-52-week-low-at-0-18-amid-steep-decline/ar-AA1y4cfB
Syros Pharmaceuticals Inc (SYRS) Stock Price Reaches $0.22: What Factors Are Influencing This Level?
January 18, 2025  |  bovnews.comB
What’s Causing Syros Pharmaceuticals Inc (SYRS) Stock’s -96.35% Drop Over the Last Six Months?
January 16, 2025  |  bovnews.comB
SYRS’s Latest Surge: What’s Behind the Spike?
January 6, 2025  |  bovnews.comB
The SYRS Conundrum: Why Syros Pharmaceuticals Inc’s Stock Is Making Headlines Again
January 2, 2025  |  bovnews.comB
Analysts Predict a $15 Target for Syros Pharmaceuticals Inc (SYRS) Stock—What Could Drive It There?
December 31, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock: More Resilient Than It Appears
December 27, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock Dive: The Hidden Causes Revealed
December 26, 2024  |  bovnews.comB
What’s Fueling Syros Pharmaceuticals Inc (SYRS) Stock’s -94.59% Loss Below Its 200-Day SMA?
December 14, 2024  |  bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illuminated Nike swoosh logo on a wall above a display pedestal with sneakers in a retail store.
Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
By Thomas Hughes | October 4, 2026
Kalshi and Polymarket logos beside a smartphone showing a prediction market on the Chiefs winning the Super Bowl, with a football in the background.
Want Private-Market Access to Kalshi and Polymarket? Try This ETF
By Jessica Mitacek | October 8, 2026
A candlestick stock price chart overlaid on a blurred urban skyline at dusk.
MarketBeat Week in Review – 09/28 - 10/02
By MarketBeat Staff | October 3, 2026
Split image showing a Carnival cruise ship at sea alongside a CarMax dealership lot with used cars displayed.
Carnival and CarMax Pop on Strong Earnings, but Challenges Remain
By Jessica Mitacek | October 3, 2026
Exterior of a CarMax dealership showing the storefront, logo signage, and parking lot with vehicles.
CarMax's Double Upgrade Could Signal a Bigger Turnaround
By Chris Markoch | October 20, 2026
Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.0003 0.00 (0.00%)
As of 10/30/2026 02:28 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0005 0.00 (-28.57%)
As of 10/30/2026 03:40 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Clever Leaves stock logo

Clever Leaves NASDAQ:CLVR

$0.01 0.00 (0.00%)
As of 10/30/2026

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0004 0.00 (0.00%)
As of 10/30/2026 03:12 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas